Abstract: The present invention introduces a novel amino acid-based cationic lipid, represented by the general formula (1), with symbols as defined herein. This lipid is pharmaceutically acceptable, biodegradable, or highly biocompatible, and offers low toxicity, low immunogenicity, and high compatibility. The amino acid or its derivatives used as starting materials are easily accessible, either naturally or through simple synthesis, making the process straightforward, safe, and cost-effective. The lipid structure may include degradable groups between the amino acid residue and lipophilic tail chains. The presence of degradable groups allows lipid nanoparticles (LNPs) to degrade within endosomes, addressing issues of LNP accumulation and endosomal acidification caused by non-degradable lipids in prior art. This facilitates the effective endosomal escape of drug molecules, such as nucleic acids, ensuring their proper cellular function after delivery.

Abstract: A cationic lipid containing a disulfide bond of Formula (1), wherein, —S—S— is a disulfide bond; L1 and L2 are each independently a degradable divalent linking group, X1 and X2 are each independently an acyclic divalent linking group containing a tertiary amine group; G1 and G2 are each independently a linking bond or a trivalent branching group; when G1 is a linking bond, k1 is 1; when G1 is a trivalent branching group, k1 is 2; when G2 is a linking bond, k1 is 1; when G2 is a trivalent branching group, k2 is 2; R1 and R2 are each independently a substituted or unsubstituted C5-30 hydrocarbon group or C5-30 hydrocarbon derivative residue. The lipid composition prepared with the cationic lipid can more effectively exert the therapeutic effect of the LNP-nucleic acid pharmaceutical composition formulation, thereby improving immunological or therapeutic outcomes.

Abstract: A novel amino acid-based cationic lipid contains unsaturated bonds, represented by the general formula (1). The amino acids or derivatives used as starting materials in the preparation process are simple and easily obtainable, offering simplicity, safety, and cost-effectiveness. The amino acid-based cationic lipid of this invention features unsaturated hydrocarbon tails and a tertiary amine moiety derived from an amino acid residue. The lipid nanoparticles (LNPs) prepared from this lipid exhibit enhanced membrane fluidity, which improves membrane fusion and facilitates cellular uptake. As a result, the delivery efficiency of the amino acid-based cationic lipid containing unsaturated bonds as a delivery material is significantly improved.

Abstract: A novel type of cationic lipid and PEGylated derivative thereof, a cationic liposome and a cationic liposome-nucleic acid pharmaceutical composition containing the cationic lipid and formulation thereof include an ionizable lipid compound of the general formula (1). This compound is slightly ionized or neutral at physiological pH but undergoes greater ionization under acidic conditions, exhibiting lower toxicity in the systemic circulation and improved endosomal escape ability. The compound's polar head contains an ionizable tertiary amine group along with a side chain containing functional groups, while the tail chains may include linking groups that are easily degraded. Cationic liposomes containing the compound have a better ability to complex with nucleic acid drugs, higher stability in serum, no apparent cytotoxicity, and high transfection efficiency.

Abstract: A novel cationic lipid having a structure as represented by general formula (1), which specifically relates to a nitrogen-containing cationic lipid, and also relates to a liposome containing the cationic lipid, a liposome pharmaceutical composition containing said cationic lipid, preparation and application thereof. A cationic liposome containing the cationic lipid represented by formula (1), can improve the loading rate and transport rate of drugs, particularly nucleic acid drugs. The terminus of the novel cationic lipid can contain a fluorescent group or a targeting group, so that the cationic liposome pharmaceutical composition containing the cationic lipid can have fluorescent or targeting function.

Abstract: A novel PEGylated lipid and preparation methods thereof, a cationic liposome containing the PEGylated lipid, a pharmaceutical composition containing the liposome, a formulation and application thereof. The PEGylated lipid can be used for modifying a liposome, and it can be further modified and coupled with a targeting group, and then used for modifying a liposome to obtain a liposome with the targeting group. Due to the presence of a long-chain PEG and the targeting group on the lipid, the modified liposome can avoid being removed by the reticuloendothelial system in a human body and realize a targeting function. Therefore, when the modified liposome delivers an active drug to cells or a patient, especially when delivering a nucleic acid or anti-tumor drug, the liposome can realize long circulation in vivo and improve the transport efficiency of drug, and has a targeting unction so the therapeutic effect of a drug is improved.

Abstract: The present invention provides a method for controlling a remote service access path including the steps of: receiving a datagram sent by any terminal intending to access the remote service; requesting a node management server to determine an optimal gateway server as an optimal node for transferring the datagram, the optimal gateway server being selected from a number of gateway servers provided for a distributed deployment architecture established for a server cluster of the remote service; testing transmission quality of a number of accessed data connections to the optimal gateway server, and determining an optimal data connection having optimal transmission quality; and invoking the optimal data connection to send a datagram after tunnel encapsulation thereof, and the optimal gateway server forwarding the datagram to a business server connected to the optimal gateway server and belonging to the server cluster.

Abstract: The present invention provides a method for controlling a remote service access path including the steps of: receiving a datagram sent by any terminal intending to access the remote service; requesting a node management server to determine an optimal gateway server as an optimal node for transferring the datagram, the optimal gateway server being selected from a number of gateway servers provided for a distributed deployment architecture established for a server cluster of the remote service; testing transmission quality of a number of accessed data connections to the optimal gateway server, and determining an optimal data connection having optimal transmission quality; and invoking the optimal data connection to send a datagram after tunnel encapsulation thereof, and the optimal gateway server forwarding the datagram to a business server connected to the optimal gateway server and belonging to the server cluster.